Wanbury Ltd.

145.00 +3.50 ▲2.5%

28 March 2024, 04:01:00 PM
Volume: 12,220

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.wanbury.com
Market Cap 477.59 Cr.
Enterprise Value(EV) 572.58 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 7.13 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 20.47 Trailing Twelve Months Ending 2023-12
Industry PE 41.54 Trailing Twelve Months Ending 2023-12
Book Value / Share -3.73 Trailing Twelve Months Ending 2023-12
Price to Book Value -39.14 Calculated using Price: 145.85
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 3.27 Cr. 32,745,498 Shares
FaceValue 10
About Wanbury Ltd.
Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury Ltd. Delivery

Delivered Qty
Traded Qty

Wanbury Ltd. Performance

1 Day
+2.47%
1 Week
+12.58%
1 Month
-17.61%
3 Month
+9.27%
6 Month
+116.10%
1 Year
+277.70%
2 Year
+60.75%
5 Year
+513.11%
10 Year
+568.20%

Wanbury Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 0 0 0 0 0 0 0 0 0
Return on Capital Employed (%) 13.85 15.27 70.48 -2 50.26 444.45 87.61 428.78 29.82
Return on Assets (%) 0.8 -1.82 15.57 -9.44 -9 23.1 -4.51 25.85 -3.22

Wanbury Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds -194 -189 -153 -185 -209 -143 -156 -23 -33 -22
Non Curr. Liab. 298 251 160 106 130 108 84 11 11 110
Curr. Liab. 265 299 402 348 362 311 355 360 320 253
Minority Int. 27 27
Equity & Liab. 396 388 409 269 283 275 284 347 298 341
Non Curr. Assets 215 224 217 192 185 182 182 174 174 184
Curr. Assets 181 164 192 78 98 94 98 171 122 157
Misc. Exp. not W/O
Total Assets 396 388 409 269 283 275 284 347 298 341

Wanbury Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 250 423 434 371 391 367 393 511 500 569
Other Income 6 1 90 77 12 46 5 5 1
Total Income 256 425 524 448 403 414 397 516 501 569
Total Expenditure -229 -391 -415 -439 -378 -389 -377 -479 -477 -503
PBIDT 28 34 108 9 25 25 20 37 24 66
Interest -19 -32 -36 -31 -40 -33 -23 -21 -21 -29
Depreciation -5 -9 -10 -10 -10 -10 -10 -11 -12 -13
Taxation -1 0 0 0 0 0 0 0 0
Exceptional Items 83 76 -1 -1
PAT 3 -7 62 -32 -25 64 -13 81 -10 23
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 3 -7 62 -32 -25 64 -13 81 -10 23
Adjusted EPS 2 -4 27 -13 -10 26 -5 25 -3 7

Wanbury Ltd. Cash Flow

Particulars 10 years 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 68 40 43 43 32 30 44 17 41 20
Cash Fr. Inv. -6 -5 -20 -13 -1 -3 64 8 1 -9
Cash Fr. Finan. -71 -30 -28 -27 -33 -27 -108 -17 -29 -32
Net Change -9 5 -5 3 -2 0 0 7 13 -21
Cash & Cash Eqvt 1 6 2 5 3 3 3 10 23 1

Wanbury Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 39.89 39.89 39.85 39.85 39.84 39.84 39.84 39.80 39.79
Public 60.11 60.11 60.15 60.15 60.16 60.16 60.16 60.20 60.21
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 76.76 76.76 76.74 76.74 0.00 76.74 76.74 76.74 76.74
No. of Shareholders (in Lacs)

Wanbury Ltd. Announcements

Fri, 29 Mar 2024
Closure of Trading Window
The Company has informed the Exchange about the Closure of Trading Window for the quarter and year ended 31st March 2024 from 01st April 2024 upto 48 hrs. from the declaration of Audited Financial Results for the quarter and year ended 31st March 2024
Wed, 27 Mar 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Fri, 22 Mar 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Expert Chemicals India Pvt Ltd

Wanbury Ltd. Technical Scans

Thu, 28 Mar 2024
Close Crossing Last Week High Close Crossing Last Week High
Opening at Low Opening at Low
Close Above Last Week High Close Above Last Week High
Making Lower Lows for 2 Days Making Lower Lows for 2 Days
High Decrease in 1 Month High Decrease in 1 Month

Wanbury Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 388,812.23 1,620.50 +0.8%
Cipla Ltd. 120,673.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 102,679.14 6,171.85 +2.0%
Zydus Lifesciences Ltd. 101,151.67 1,007.35 +0.8%
Mankind Pharma Ltd. 92,029.19 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 91,330.58 6,347.35 +1.9%
Divi's Laboratories Ltd. 91,234.91 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.66 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 32.54 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.64 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.01 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 53.29 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.71 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 65.97 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.23 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.66 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.82 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.37 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.36 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.52 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 7.00 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Wanbury Ltd. FAQ's

What is Wanbury share price?

Can I buy Wanbury shares now?

What is the Market Cap of Wanbury?

What are the key metrics to analyse Wanbury?

What is the 52 Week High and Low of Wanbury?

What is the trend of Wanbury share price?